Similar rates of stent thrombosis seen at three years for zotarolimus- and sirolimus-eluting stents
WEDNESDAY, Aug. 29 (HealthDay News) -- Two types of drug-eluting stents with distinct antiproliferative properties have similar long-term rates of stent thrombosis and outcomes, including death and heart attack, according to a study published online Aug. 27 in The Lancet to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 25 to 29 in Munich.
Edoardo Camenzind, M.D., from the University of Geneva, and colleagues randomly assigned 8,709 patients undergoing coronary artery procedures to receive the Endeavor zotarolimus-eluting stent (E-ZES; 4,357 patients) or the Cypher sirolimus-eluting stent (C-SES; 4,352 patients).
The researchers found that, after three years, the rates of definite or probable stent thrombosis were similar for the E-ZES (1.4 percent; predicted, 1.5 percent) and C-SES (1.8 percent; predicted, 2.5 percent) groups (hazard ratio, 0.81; P = 0.22). The two groups also had similar rates of outcomes, including death, myocardial infarction, stroke, and major bleeding. Dual antiplatelet treatment use was similar in both groups and was used by 96 percent of patients at discharge, 88 percent at one year, 37 percent at two years, and 30 percent at three years.
"No evidence of superiority of E-ZES compared with C-SES in definite or probable stent thrombosis rates was noted at three years," Camenzind and colleagues conclude. "Time analysis suggests a difference in definite or probable stent thrombosis between groups is emerging over time, and a longer follow-up is therefore needed given the clinical relevance of stent thrombosis."
Several authors disclosed financial ties to pharmaceutical and medical device companies, including Medtronic, which funded the study and manufactures E-ZES, and Cordis, which manufactures C-SES.
Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
More Information